



IFW

S&H Form: (02/05)

**REPLY/AMENDMENT  
FEE TRANSMITTAL**

<b>REPLY/AMENDMENT FEE TRANSMITTAL</b>		Attorney Docket No.	1454.1685	
		Application Number	10/571,669	
		Filing Date	March 13, 2006	
		First Named Inventor	Bernd SCHUERMANN et al.	
		Group Art Unit	Unassigned	
AMOUNT ENCLOSED	0.00	Examiner Name	Unassigned	

**FEES CALCULATION (fees effective 12/08/04)**

CLAIMS AS AMENDED	Claims Remaining After Amendment	Highest Number Previously Paid For	Number Extra	Rate	Calculations
TOTAL CLAIMS	9	- 20 =	0	X \$ 50.00 =	\$ 0.00
INDEPENDENT CLAIMS	2	- 3 =	0	X \$ 200.00 =	0.00

Since an Official Action set an original due date of , petition is hereby made for an extension to cover the date this reply is filed for which the requisite fee is enclosed (1 month (\$120)); (2 months (\$450)); (3 months (\$1,020)); (4 months (\$1,590)); (5 months (\$2,160));

If Notice of Appeal is enclosed, add (\$500.00)

If Statutory Disclaimer under Rule 20(d) is enclosed, add fee (\$130.00)

Information Disclosure Statement (Rule 1.17(p)) (\$180.00)

Total of above Calculations = \$ 0.00

Reduction by 50% for filing by small entity (37 CFR 1.9, 1.27 & 1.28)

**TOTAL FEES DUE = \$ 0.00**

(1) If entry (1) is less than entry (2), entry (3) is "0".

(2) If entry (2) is less than 20, change entry (2) to "20".

(4) If entry (4) is less than entry (5), entry (6) is "0".

(5) If entry (5) is less than 3, change entry (5) to "3".

**METHOD OF PAYMENT**

- Check enclosed as payment.
- Charge "TOTAL FEES DUE" to the Deposit Account No. below.
- No payment is enclosed.

**GENERAL AUTHORIZATION**


- If the above-noted "AMOUNT ENCLOSED" is not correct, the Commissioner is hereby authorized to credit any overpayment or charge any additional fees necessary to:

Deposit Account No. 19-3935

Deposit Account Name STAAS & HALSEY LLP

- The Commissioner is also authorized to credit any overpayments or charge any additional fees required under 37 CFR 1.16 (filing fees) or 37 CFR 1.17 (processing fees) during the prosecution of this application, including any related application(s) claiming benefit hereof pursuant to 35 USC § 120 (e.g., continuations/divisionals/CIPs under 37 CFR 1.53(b) and/or continuations/divisionals/CPAs under 37 CFR 1.53(d)) to maintain pendency hereof or of any such related application.

**SUBMITTED BY: STAAS & HALSEY LLP**

Typed Name	Mark J. Henry	Reg. No.	36,162
Signature		Date	Nov 13 2006

©2005 Staas & Halsey LLP



Docket No.: 1454.1685

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Bernd SCHUERMANN et al.

Serial No. 10/571,663

Group Art Unit: Unassigned

Confirmation No. Unassigned

Filed: March 13, 2006

Examiner: Unassigned

For: IDENTIFICATION OF PHARMACEUTICAL TARGETS

**SECOND PRELIMINARY AMENDMENT**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

Before examination of the above-identified application, please amend the application as follows: